Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new ...
Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...
Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...
After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track ...
JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...
Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement ...
Dynavax expects HEPLISAV-B product revenue in 2025 to range between $305 million and $325 million, representing a 17% year-over-year growth at the midpoint. The company anticipates achieving key ...
Dynavax is currently conducting a randomized, active-controlled, dose escalation, multicenter Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to ...
HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback